FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1845-1853 June 13, 2002 Number 24 Next

Abstract PDF PDA Full Text PowerPoint Slide Set Editorial by Hare, J. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach.

Methods Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained. The primary end points were the New York Heart Association functional class, quality of life, and the distance walked in six minutes.

Results As compared with the control group, patients assigned to cardiac resynchronization experienced an improvement in the distance walked in six minutes (+39 vs. +10 m, P=0.005), functional class (P<0.001), quality of life (–18.0 vs. –9.0 points, P= 0.001), time on the treadmill during exercise testing (+81 vs. +19 sec, P=0.001), and ejection fraction (+4.6 percent vs. –0.2 percent, P<0.001). In addition, fewer patients in the group assigned to cardiac resynchronization than control patients required hospitalization (8 percent vs. 15 percent) or intravenous medications (7 percent vs. 15 percent) for the treatment of heart failure (P<0.05 for both comparisons). Implantation of the device was unsuccessful in 8 percent of patients and was complicated by refractory hypotension, bradycardia, or asystole in four patients (two of whom died) and by perforation of the coronary sinus requiring pericardiocentesis in two others.

Conclusions Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay.

Devices that make use of atrial-synchronized biventricular pacing to coordinate right and left ventricular contraction have been developed, and early studies have suggested that short- and long-term cardiac resynchronization can improve cardiac function and enhance functional capacity and the quality of life.^{11,12,13,14,15,16,17,18,19} However, previous studies evaluated only small numbers of patients and either were uncontrolled or were not carried out in a double-blind manner.

We report the results of the Multicenter InSync Randomized Clinical Evaluation (MIRACLE), a double-blind study of cardiac resynchronization in patients with moderate-to-severe heart failure and a prolonged QRS interval.

Methods

Patients

Patients were eligible for the study if they had moderate or severe (New York Heart Association functional class III or IV) chronic heart failure due to either ischemic or nonischemic cardiomyopathy. All patients had a left ventricular ejection fraction of 35 percent or less, a left ventricular end-diastolic dimension of 55 mm or more, a QRS interval of 130 msec or more, and a six-minute walking distance of 450 m or less. Patients received all appropriate treatments for heart failure, which included a diuretic, an angiotensin-converting–enzyme inhibitor or an angiotensin-receptor blocker, and (usually) digitalis and a beta-blocker. The doses of these background medications were stable for at least one month, except for doses of the beta-blocker (which were stable for three months).

Patients were excluded if they had a pacemaker or cardioverter–defibrillator or had an indication for or a contraindication to cardiac pacing, if they had had a cardiac or cerebral ischemic event within the previous three months, or if they had had an atrial arrhythmia within the previous month. In addition, patients were not allowed to participate if they had a systolic blood pressure of more than 170 or less than 80 mm Hg, a heart rate of more than 140 beats per minute, a serum creatinine level of more than 3.0 mg per deciliter (265 µmol per liter), or serum aminotransferase levels more than three times the upper limit of normal. Other reasons for exclusion have been described previously.²⁰ The institutional review board of each center approved the study protocol, and all patients gave written informed consent.

Study Design

Patients meeting the criteria for entry underwent the following evaluations at base line: New York Heart Association class,²¹ six-minute walking test,²² maximal treadmill exercise test (with the use of the modified Naughton protocol²³), quality-of-life evaluation (with the use of the Minnesota Living with Heart Failure Questionnaire²⁴), two-dimensional Doppler-flow echocardiography (to assess the left ventricular ejection fraction, the internal diastolic dimensions, and the degree of mitral regurgitation), and QRS interval (from a 12-lead electrocardiogram).

After this initial evaluation, patients underwent implantation of a cardiac-resynchronization device (InSync model 8040, Medtronic) along with three pacing leads: a standard right atrial lead, a standard right ventricular lead, and a specialized left ventricular lead,²⁵ which was placed into a distal cardiac vein by way of the coronary sinus through a guiding catheter. Patients who had undergone successful implantation were randomly assigned to atrial-synchronized biventricular pacing (the resynchronization group) or to a control group (no pacing) for six months, during which time medications for heart failure were to be kept constant. Randomization occurred in permuted blocks to ensure a balance between groups within centers. Base-line variables were reevaluated one, three, and six months after randomization. Crossover from the control mode to the cardiac-resynchronization mode before the six-month assessment was prohibited, except for patients in whom a bradyarrhythmia that required cardiac pacing developed. Neither the patients nor the physicians treating them for heart failure and performing the study evaluations were aware of the treatment assignment. At each site, an electrophysiologist, who was otherwise uninvolved with clinical care, opened a sealed envelope at the time of randomization, programmed the device, and performed all tests that could reveal the identity of the assigned pacing mode.

Statistical Analysis

The study had three primary end points (the New York Heart Association class, the quality-of-life score, and the distance walked in six minutes) and several secondary end points (peak oxygen consumption, time on a treadmill, left ventricular ejection fraction and end-diastolic dimension, severity of mitral regurgitation, duration of QRS interval, and a clinical composite response, which assigns patients to one of three response groups — improved, worsened, or unchanged — as previously defined^20,26) as the major efficacy variables for the study. In addition, the protocol specified an analysis of death or worsening heart failure (as safety variables), as well as the number of days spent in the hospital (as part of the assessment of utilization of heath care resources).

All end points were analyzed according to the intention-to-treat principle; patients who crossed over were analyzed according to their original treatment assignment. For continuous variables, comparisons of changes from base line to the six-month visit between the control group and the resynchronization group were evaluated for significance with the use of the Wilcoxon rank-sum test. For categorical end points, differences in the distribution of responses to treatment at six months in the two groups were compared with the use of a chi-square test. Only patients for whom data were available at base line and at six months were included in these analyses, but the results were similar if patients with incomplete data were also included and had their last available double-blind value carried forward. Cumulative survival curves for the risk of a major clinical event were constructed according to the Kaplan–Meier method,²⁷ and differences between the curves were tested for significance by the log-rank statistic.²⁸ Cox proportional-hazards regression models²⁹ were used to estimate hazard ratios.

For the primary efficacy variables, the study would achieve its prespecified objective if the difference between the groups in all three end points had a P value less than or equal to 0.05, if two had a P value less than or equal to 0.025, or if one had a P value less than or equal to 0.0167. The sample size (224 patients per treatment group) was estimated on the basis of the assumption that the study would have 80 percent power (two-sided alpha, 0.0167) to detect a difference in New York Heart Association class of 0.75, quality of life of 13 points, or distance walked in six minutes of 50 m. For secondary end points, a P value of less than 0.05 was used to assess statistical significance.

Investigators had full access to all data and performed analyses without restrictions or limitations from the sponsor. Data are presented as median changes from base line to six months (with 95 percent confidence intervals). All P values are two-sided.

Results

Between November 1998 and December 2000, 571 patients at 45 centers agreed to participate in the study. Of these, 47 patients were not enrolled because the device was not successfully implanted (43 patients), the patient required cardiac pacing (2 patients), or the patient's condition became clinically unstable (2 patients). Seventy-one patients underwent randomization but agreed to be enrolled in an initial pilot phase of the study, which followed patients for only three months. The remaining 453 patients (who made up the patients described in this report) were enrolled in the main six-month study; 225 patients were randomly assigned to the control group, and 228 patients were randomly assigned to the cardiac-resynchronization group. The two groups were similar with respect to all base-line characteristics (Table 1).

View this table: [in this window] [in a new window]   Table 1. Base-Line Characteristics of the Study Patients.

 
Follow-up and Disposition of Patients

Of the 225 patients assigned to the control group, 24 did not complete six months of follow-up — 16 died, 2 received a heart transplant, 1 had complications related to the device, and 5 missed the six-month visit. Of the 228 patients assigned to cardiac resynchronization, 13 did not complete six months of follow-up — 12 died and 1 had complications related to the device. No patient was lost to follow-up for the analysis of death or worsening heart failure.

All patients continued to receive the assigned treatment for the intended duration of the study, except for 10 patients in the control group who had their device reprogrammed to the cardiac-resynchronization mode, 7 because of worsening heart failure and 3 because of bradycardia.

Effect on Primary End Points

As compared with the control group, patients assigned to cardiac resynchronization had improvements in the distance walked in six minutes, the quality-of-life score, and the New York Heart Association functional class (P=0.005, P=0.001, and P<0.001, respectively) (Table 2). Differences in favor of cardiac resynchronization were apparent as early as after one month of treatment, and the magnitude of improvement was maintained without attenuation for the entire study period (Figure 1). The magnitude of the effect on the three primary end points was not influenced by the use of a beta-blocker, the cause of heart failure (ischemic or nonischemic), the configuration of the QRS complex (left or right bundle-branch block), or the base-line duration of the QRS interval (analyzed as a continuous variable, P>0.10 for all interactions).

View this table: [in this window] [in a new window]   Table 2. Effect of Cardiac Resynchronization on Efficacy End Points.

 

View larger version (14K): [in this window] [in a new window]   Figure 1. Change in the Distance Walked in Six Minutes and the Quality-of-Life Score. Shown are median changes (with 95 percent confidence intervals) one, three, and six months after randomization in the control group (circles) and the cardiac-resynchronization group (diamonds). P values are for the comparison between groups. For each variable, data are shown for patients who had values at all three time points (for the six-minute walk, 196 patients in the control group and 212 patients in the resynchronization group; for the quality-of-life score, 192 patients and 211 patients, respectively).

 
Effect on Secondary End Points

As compared with the control group, patients in the resynchronization group had an improvement in the two measures of maximal exercise performance: peak oxygen consumption (P=0.009) and total exercise time (P=0.001) (Table 2). Furthermore, the left ventricular ejection fraction increased and the end-diastolic dimension, the area of the mitral regurgitant jet, and the duration of the QRS interval all decreased in the resynchronization group (all P<0.001 for the comparison with the control group) (Table 2). Finally, cardiac resynchronization had a highly favorable effect on the clinical composite heart-failure score. At the end of six months, the condition of more patients in the group assigned to cardiac resynchronization was considered to have improved (67 percent, vs. 39 percent in the control group) and that of fewer was considered to have worsened (16 percent vs. 27 percent) (P<0.001).

Effect on Death and on Worsening Heart Failure

In the intention-to-treat analysis, there were 16 deaths in the control group and 12 deaths in the resynchronization group. During the six-month follow-up period, there were 50 hospitalizations for heart failure in 34 control patients, for a total of 363 hospital days for heart failure, but there were only 25 hospitalizations for heart failure in 18 patients in the resynchronization group, for a total of 83 hospital days for heart failure. Differences between the groups in the frequency of hospitalization or the use of an intravenous medication for worsening heart failure were significant (P=0.02 and P=0.004, respectively) (Table 3).

View this table: [in this window] [in a new window]   Table 3. Clinical Events during the Double-Blind Treatment Period.

 
In an analysis of time to a first event, 44 patients (20 percent) in the control group but only 28 patients (12 percent) in the resynchronization group died or were hospitalized for worsening heart failure (Figure 2). The risk of a major clinical event was 40 percent lower in the resynchronization group (95 percent confidence interval, 4 to 63 percent; P=0.03). Favorable effects of cardiac resynchronization were also seen when episodes of worsening heart failure requiring the use of intravenous drugs were included in the analysis (P=0.02) (Table 3).

View larger version (13K): [in this window] [in a new window]   Figure 2. Kaplan–Meier Estimates of the Time to Death or Hospitalization for Worsening Heart Failure in the Control and Resynchronization Groups. The risk of an event was 40 percent lower in the resynchronization group (95 percent confidence interval, 4 to 63 percent; P=0.03).

 
As compared with the control group, patients in the resynchronization group were more likely to be hospitalized for repositioning or replacement of the left ventricular lead (11 and 3 patients in the resynchronization and control groups, respectively). However, the two treatment groups were similar with respect to hospitalizations not related to heart failure or to the function of the left ventricular lead (37 and 33 hospitalizations in the resynchronization and control groups, respectively).

Adverse Events

Of the 571 participating patients, 4 did not undergo randomization because of adverse clinical events during the implantation procedure. Complete heart block that required permanent cardiac pacing developed in two patients; progressive hypotension developed in one patient, who died later the same day; and one patient had asystole and required cardiopulmonary resuscitation, did not recover neurologically, and died one month later. In addition, during the procedure, 23 patients (4 percent) had a coronary-sinus dissection, and 12 patients (2 percent) had a cardiac-vein or coronary-sinus perforation. Of these, three required intravenous catecholamines, pericardiocentesis, or both for a presumed or confirmed diagnosis of hemopericardium but recovered without sequelae and continued in the study.

Of the 528 patients who underwent successful implantation, the median duration of the procedure was 2.7 hours (range, 0.9 to 7.3). After implantation, 20 patients required repositioning of the left ventricular lead and 10 required its replacement; 7 patients reported a pacemaker-related infection that required explantation, 4 of whom had the device reimplanted uneventfully. The rate of device-related events was substantially lower than the rates described in the prespecified criteria established in the original study protocol.²⁰ The frequency of adverse events unrelated to the device or to heart failure did not differ significantly between the two treatment groups.

Discussion

The results of the present study indicate that cardiac resynchronization improves a broad range of measures of cardiac function and clinical status in patients with moderate-to-severe heart failure and a prolonged QRS interval. Cardiac resynchronization reduced the degree of ventricular dyssynchrony (as evidenced by a shortened duration of the QRS interval), and this effect was accompanied by both an increase in the left ventricular ejection fraction and a decrease in the left ventricular end-diastolic dimension and in the magnitude of mitral regurgitation. As a result, as compared with the control group, patients in the cardiac-resynchronization group had significant improvements in functional capacity, clinical status, and quality of life. Resynchronization also enhanced both maximal and submaximal exercise capacity (assessed by a treadmill test and the distance walked in six minutes, respectively). The magnitude of these hemodynamic and clinical benefits was similar to (if not greater than) that reported with effective pharmacologic interventions for heart failure,^30,31,32,33 and yet they were seen in patients already receiving these drugs.

Cardiac resynchronization not only increased the likelihood of clinical improvement, but also reduced the risk of clinical deterioration during the course of follow-up. Patients in the resynchronization group were less likely than those in the control group to require treatment with an intravenous medication for worsening heart failure. Furthermore, cardiac resynchronization was associated with fewer admissions to the hospital and with fewer days in the hospital for the treatment of heart failure. The combined risk of a major clinical event (death or hospitalization for heart failure) was 40 percent lower in the resynchronization group than in the control group (Figure 2). Yet, even though background therapy was intensified more frequently in the control group, these patients had fewer hemodynamic and clinical benefits at the end of double-blind treatment than those in the resynchronization group.

Implantation and maintenance of a resynchronization device were associated with risks that were greater than those of a conventional pacing device. During implantation, a resynchronization device — unlike conventional pacemakers — requires the insertion of an additional pacing lead into the coronary sinus, which is advanced into a cardiac vein to allow pacing of the left ventricle.²⁵ In some patients, efforts to implant the lead were unsuccessful (about 8 percent) or were accompanied by dissection or perforation of the coronary sinus or cardiac vein (about 6 percent). Although these events are generally asymptomatic, attempts to implant the lead or the device may have serious complications, including complete heart block, hemopericardium, and cardiac arrest (which together occurred in about 1.2 percent of patients). The left ventricular lead may also become dislodged during long-term pacing (which occurred in about 6 percent) and may require repositioning or replacement,³⁴ but this did not result in the discontinuation of treatment in any patient. When all possible reasons for technical failure were considered, about 8 percent of the 571 participating patients were unable to receive and be maintained on resynchronization therapy for the planned duration of treatment.

Our findings are consistent with the results of earlier studies that reported both hemodynamic and symptomatic improvement after cardiac resynchronization.^{11,12,13,14,15,16,17,18,19} These reports were difficult to interpret, however, because the studies evaluated only small numbers of patients, had a high proportion of patients who did not complete the study, and failed to ensure that patients or investigators were unaware of the identity of the treatment assignment. Our study did not suffer from these limitations. However, we evaluated the effects of cardiac resynchronization in a double-blind manner for only six months. Although the duration was longer than that of earlier controlled studies of resynchronization and similar to that of many trials of pharmacologic treatments, the outcomes, both beneficial and adverse, reported in a study of 500 patients evaluated for six months may not reflect the effects seen in thousands of patients treated for years.^35,36,37,38 Nevertheless, the effects of resynchronization on the combined risk of death and worsening heart failure seen in this study are encouraging. Large-scale, controlled trials to evaluate the effects of cardiac resynchronization on the natural history of heart failure are now in progress.^39,40

Supported by Medtronic. Drs. Abraham, Fisher, Packer, and Hayes are consultants to Medtronic. Dr. Hayes also owns stock in Medtronic, Guidant, and St. Jude Medical.

^* Participating investigators and study centers of the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) are listed in the Appendix.

Source Information

From the University of Kentucky College of Medicine, Lexington (W.T.A., W.G.F.); Emory University and Crawford Long Hospital, Atlanta (A.L.S., D.B.D., A.R.L.); the University of Pennsylvania, Philadelphia (E.L., D.Z.K.); Columbia University College of Physicians and Surgeons, New York (M.P.); Mayo Medical Center, Rochester, Minn. (A.L.C., D.L.H.); and Long Beach Memorial Medical Center, Long Beach, Calif. (M.E., J.M.).

Other authors were Robin J. Trupp, M.S.N. (University of Kentucky, Lexington), Jackie Underwood, B.S.N. (Emory University and Crawford Long Hospital, Atlanta), Faith Pickering, B.S.N. (University of Pennsylvania, Philadelphia), Cindy Truex, B.S.N. (Mayo Medical Center, Rochester, Minn.), and Peggy McAtee, M.S.N. (Long Beach Memorial Hospital, Long Beach, Calif.).

Address reprint requests to Dr. Abraham at the University of Kentucky College of Medicine, Division of Cardiovascular Medicine, Rm. L-543, Kentucky Clinic, 740 S. Limestone St., Lexington, KY 40536-0284, or at wtabra2{at}uky.edu.

References

1. Farwell D, Patel NR, Hall A, Ralph S, Sulke AN. How many people with heart failure are appropriate for biventricular resynchronization? Eur Heart J 2000;21:1246-1250. [Free Full Text]
2. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-2667. [Free Full Text]
3. Xiao HB, Brecker SJ, Gibson DG. Effects of abnormal activation on the time course of the left ventricular pressure pulse in dilated cardiomyopathy. Br Heart J 1992;68:403-407. 
4. Littmann L, Symanski JD. Hemodynamic implications of left bundle branch block. J Electrocardiol 2000;33:Suppl:115-121.
5. Saxon LA, Kerwin WF, Cahalan MK, et al. Acute effects of intraoperative multisite ventricular pacing on left ventricular function and activation/contraction sequence in patients with depressed ventricular function. J Cardiovasc Electrophysiol 1998;9:13-21. [ISI][Medline]
6. Kerwin WF, Botvinick EH, O'Connell JW, et al. Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol 2000;35:1221-1227. [Free Full Text]
7. Xiao HB, Roy C, Fujimoto S, Gibson DG. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol 1996;53:163-170. [CrossRef][ISI][Medline]
8. Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-152. [CrossRef][ISI][Medline]
9. Shamim W, Francis DP, Yousufuddin M, et al. Intraventricular conduction delay: a prognostic marker in chronic heart failure. Int J Cardiol 1999;70:171-178. [CrossRef][ISI][Medline]
10. Brophy JM, Deslauriers G, Rouleau JL. Long-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1994;10:543-547. [ISI][Medline]
11. Leclercq C, Cazeau S, Le Breton H, et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol 1998;32:1825-1831. [Free Full Text]
12. Kass DA, Chen CH, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999;99:1567-1573. [Free Full Text]
13. Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999;99:2993-3001. [Free Full Text]
14. Gras D, Mabo P, Tang T, et al. Multisite pacing as a supplemental treatment of congestive heart failure: preliminary results of the Medtronic Inc. InSync Study. Pacing Clin Electrophysiol 1998;21:2249-2255. [CrossRef][Medline]
15. Leclercq C, Cazeau S, Ritter P, et al. A pilot experience with permanent biventricular pacing to treat advanced heart failure. Am Heart J 2000;140:862-870. [CrossRef][ISI][Medline]
16. Etienne Y, Mansourati J, Touiza A, et al. Evaluation of left ventricular function and mitral regurgitation during left ventricular-based pacing in patients with heart failure. Eur J Heart Fail 2001;3:441-447. [CrossRef][ISI][Medline]
17. Lau CP, Yu CM, Chau E, et al. Reversal of left ventricular remodeling by synchronous biventricular pacing in heart failure. Pacing Clin Electrophysiol 2000;23:1722-1725. [Medline]
18. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-880. [Free Full Text]
19. Braunschweig F, Linde C, Gadler F, Ryden L. Reduction of hospital days by biventricular pacing. Eur J Heart Fail 2000;2:399-406. [CrossRef][ISI][Medline]
20. Abraham WT. Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). J Card Fail 2000;6:369-380. [CrossRef][ISI][Medline]
21. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown, 1994.
22. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923. [Abstract]
23. Naughton JP, Maider R. Methods of exercise testing. In: Naughton JP, Hellerstein HR, eds. Exercise testing and exercise training in coronary artery disease. New York: Academic Press, 1973:79-91.
24. Rector RS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. II. Content, reliability, and validity of a new measure — the Minnesota Living with Heart Failure Questionnaire. Heart Fail 1987;3:198-209.
25. Daubert JC, Ritter P, Le Breton H, et al. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing Clin Electrophysiol 1998;21:239-245. [CrossRef][Medline]
26. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001;7:176-182. [CrossRef][ISI][Medline]
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
28. Savage IR. Contributions to the theory of rank order statistics — the two-sample case. Ann Math Stat 1956;27:590-615.
29. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-202.
30. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1-7. [Free Full Text]
31. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-544. [Abstract]
32. Gundersen T, Swedberg K, Amtorp O, Remes J, Nilsson B. Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Eur Heart J 1994;15:1659-1665. [Free Full Text]
33. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Circulation 1996;94:2793-2799. [Free Full Text]
34. Valls-Bertault V, Mansourati J, Gilard M, Etienne Y, Munier S, Blanc JJ. Adverse events with transvenous left ventricular pacing in patients with severe heart failure: early experience from a single centre. Europace 2001;3:60-63. [Free Full Text]
35. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155. [Free Full Text]
36. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-1816. [Free Full Text]
37. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752. [CrossRef][ISI][Medline]
38. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -- the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587. [CrossRef][ISI][Medline]
39. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. J Card Fail 2000;6:276-285. [CrossRef][ISI][Medline]
40. Cleland JGF, Daubert JC, Erdmann E, et al. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 2001;3:481-489. [CrossRef][ISI][Medline]

The following investigators and study centers participated in MIRACLE: Clinical Events Review Committee: W. Abraham (chair), A. Curtis, D. Hayes, E. Loh, J. Sackner-Bernstein, A. Tang; Safety Monitoring Board: G. Francis (chair), G. Crossley, S. Norsted, J. Young; Operations Team (Medtronic): V. Manda, S. Petersen-Stejskal, J. Johnson, L. Ford, K. Kruger, M. Hill, D. Smith; Echocardiography Core Laboratory (University of Pennsylvania): M. St. John Sutton, T. Plappert; Cardiopulmonary Exercise Core Laboratory (University of Cincinnati): L. Wagoner, P. Zengel; Study Centers: Baylor College of Medicine, Houston: G. Torre, J.-B. Durand, J. Seger, W. Spencer, D. Killip, J. Vinluan; Brigham and Women's Hospital, Boston: L. Stevenson, M. Sweeney, L. Roberts, M. Brophy, K. Corrigan; Cardiac Solutions, Sun City, Ariz.: J. Caplan, G. Wong, E. Daniel, J. Brockhaus; Cardiology Associates of Lubbock, Lubbock, Tex.: C. Rizo-Patron, J. Zias, K. Belco, D. Stone; Christ Hospital, Chicago: M. Silver, M. Dia, K. Wesselhoff, J. Tischer; Columbia Presbyterian Hospital, New York: E. Horn, H. Spotnitz, M. Yushak, N. Medina, M. Kral; Crawford Long Hospital, Atlanta: D. Delurgio, A. Leon, J. Schmidt, J. Underwood, N. VanHouten; Duke University, Durham, N.C.: C. O'Connor, R. Sorrentino, D. LeLoudis; Emory University, Atlanta: A. Smith, J. Langberg, S. Heeke; Henry Ford Hospital, Detroit: P. McCullough, C. Schuger, D. Frankovich, J. Lehman; Iowa Heart Center, Des Moines: W. Wickemeyer, B. Johnson, B. Sollinger, J. Greene; London Health Sciences Centre, London, Ont., Canada: R. Yee, J. Finan; Long Beach Memorial Medical Center, Long Beach, Calif.: M. Ellestad, J. Messenger, P. McAtee, B. Easterbrook, P. Long; Mayo Medical Center, Rochester, Minn.: A. Clavell, D. Hayes, C. Truex, J. Trusty; McGuire Veterans Affairs Medical Center, Richmond, Va.: P. Mohanty, D. Gilligan, A. Hirsch; Medical College of Virginia, Richmond: M. Hess, K. Ellenbogen, S. Constantino; Medical College of Wisconsin, Milwaukee: M. Cinquegrani, J. Roth, M. Ptacin, S. Mauermann, S. Owen; Mid-America Heart Institute, Kansas City, Mo.: D. Bresnahan, D. Steinhaus, K. Vlach, A. Stewart, B. Pritchard; Montefiore Medical Center, Bronx, N.Y.: R. Moskowitz, J. Gross, S. Hanson, M. Galvao; Montreal Heart Institute, Montreal: B. Thibault, N. Cuerrien; Ochsner Clinic, New Orleans: M. Mehra, B. Robcheaux; Prairie Heart Institute, Springfield, Ill.: S. Jennison, B. Miller, K. Moulton, J. Mullin, L. Clark-Kater, K. Laswell, L. Moulton, C. Call; Quebec Heart Institute, Ste.-Foy, Que., Canada: F. Philippon, L. Charbonneau; Sentara Virginia Beach Hospital, Virginia Beach, Va.: S. Jones, L. Kanter, B. Bariciano, P. Farrar; Southwest Florida Heart Group, Fort Myers: M. Danzig, E. Burton, M. Barr; Spartanburg Regional Healthcare System, Spartanburg, S.C.: D. Ike, D. Rodak, D. Weathers, N. Sprouse; St. Luke's–Roosevelt Hospital Center, New York: J. Sackner-Bernstein, J. Steinberg, A. Alburo; St. Michael's Hospital, Toronto: D. Newman, P. Dorian, S. Thorne; St. Thomas Hospital, Nashville: D. Pearce, J. Baker, T. Smith, J. Sensing; Tampa General Hospital, Tampa, Fla.: E. Spoto, S. Mester, S. Sweeny; University of Alabama, Birmingham: R. Bourge, N. Kay, A. Epstein, J. Strobel, J. Saxon, R. Griffith, R. Bubien, J. Slabaugh; University of Arkansas for Medical Sciences, Little Rock: J. Joseph, J. Bissett, T. Antakli, M. DeMarco, J. Ginnette-Clark, B. Alm; University of California, San Diego: B. Greenberg, G. Feld, A. Maisel, B. Hamilton, L. Tone; University of Cincinnati, Cincinnati: S. Menon, L. Wagoner, R. Henthorn, J. Boroughs, G. Conway, D. Lameier; University of Florida, Gainesville: J. Aranda, A. Curtis, D. Leach, L. King; University of Kentucky, Lexington: W. Abraham, W. Fisher, S. Lamba, R. Trupp, K. Martinez, C. Brann; University of Maryland, Baltimore: M. Gold, H. Scott; University of Oklahoma, Oklahoma City: P. Adamson, D. Reynolds, G. Straughn, A. Luby; University of Ottawa, Ottawa, Ont., Canada: S. Smith, A. Tang, C. Carey, P. Theoret-Patrick; University of Pennsylvania, Philadelphia: E. Loh, S. Brozena, D. Kocovic, F. Pickering, L. Goffredo, K. Craig; University of Rochester Medical Center, Rochester, N.Y.: C.-S. Liang, J. Daubert, C. Edgett, B. Del Pappa, E. Perkin; University of Washington Medical Center, Seattle: D. Fishbein, A. Zivin, J. Poole, C. Mitchell, B. Letterer; Vanderbilt University Medical Center, Nashville: J. Wilson, M. Wathen, A. Delmotte, S. Hanamanthu, M. Otwell, N. Connors; Wake Forest Baptist Medical Center, Winston-Salem, N.C.: T. Wannenburg, W. Haisty, S. Jordan, L. Triplet; Washington Hospital Center, Washington, D.C.: R. Cooke, S. O'Donohue, C. Bither, D. Obias-Manno.

Abstract PDF PDA Full Text PowerPoint Slide Set Editorial by Hare, J. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

Cardiac Resynchronization Therapy for Heart Failure
Bax J. J., Van der Wall E. E., Schalij M. J., Gottlieb S. S., Fisher M. L., Abraham W. T., the MIRACLE Study Group
Extract | Full Text | PDF  
N Engl J Med 2002; 347:1803-1804, Nov 28, 2002. Correspondence

This article has been cited by other articles:

• Stanton, T., Hawkins, N. M., Hogg, K. J., Goodfield, N. E.R., Petrie, M. C., McMurray, J. J.V. (2008). How should we optimize cardiac resynchronization therapy?. Eur Heart J 0: ehn380v1-15 [Abstract] [Full Text]  
• Valzania, C., Eriksson, M. J., Boriani, G., Gadler, F. (2008). Cardiac resynchronization therapy during rest and exercise: comparison of two optimization methods. Europace 0: eun216v1-9 [Abstract] [Full Text]  
• Buck, S., Maass, A. H., Nieuwland, W., Anthonio, R. L., Van Veldhuisen, D. J., Van Gelder, I. C. (2008). Impact of interventricular lead distance and the decrease in septal-to-lateral delay on response to cardiac resynchronization therapy. Europace 0: eun208v1-7 [Abstract] [Full Text]  
• Sood, M. M., Pauly, R. P., Rigatto, C., Komenda, P. (2008). Left ventricular dysfunction in the haemodialysis population. NDT Plus 1: 199-205 [Abstract] [Full Text]  
• Chang, S-A, Kim, H-K, Lee, H-Y, Choi, S-Y, Koo, B-K, Kim, Y-J, Sohn, D-W, Oh, B-H, Park, Y-B, Choi, Y-S, Kang, H-J, Kim, H-S (2008). Restoration of left ventricular synchronous contraction after acute myocardial infarction by stem cell therapy: new insights into the therapeutic implication of stem cell therapy for acute myocardial infarction. Heart 94: 995-1001 [Abstract] [Full Text]  
• Bordachar, P., Iriart, X., Chabaneix, J., Sacher, F., Lafitte, S., Jais, P., Haissaguerre, M., Clementy, J., Dos Santos, P., Thambo, J.-B. (2008). Presence of ventricular dyssynchrony and haemodynamic impact of right ventricular pacing in adults with repaired Tetralogy of Fallot and right bundle branch block. Europace 10: 967-971 [Abstract] [Full Text]  
• Lim, S. H., Lip, G. Y.H., Sanderson, J. E. (2008). Ventricular optimization of biventricular pacing: a systematic review. Europace 10: 901-906 [Abstract] [Full Text]  
• Gradaus, R, Stuckenborg, V, Loher, A, Kobe, J, Reinke, F, Gunia, S, Vahlhaus, C, Breithardt, G, Bruch, C (2008). Diastolic filling pattern and left ventricular diameter predict response and prognosis after cardiac resynchronisation therapy. Heart 94: 1026-1031 [Abstract] [Full Text]  
• Miura, M., Wakayama, Y., Endoh, H., Nakano, M., Sugai, Y., Hirose, M., ter Keurs, H. E., Shimokawa, H. (2008). Spatial non-uniformity of excitation-contraction coupling can enhance arrhythmogenic-delayed afterdepolarizations in rat cardiac muscle. Cardiovasc Res 0: cvn162v2-7 [Abstract] [Full Text]  
• Remme, W. J., McMurray, J. J.V., Hobbs, F.D. R., Cohen-Solal, A., Lopez-Sendon, J., Boccanelli, A., Zannad, F., Rauch, B., Keukelaar, K., Macarie, C., Ruzyllo, W., Cline, C., for the SHAPE Study Group, (2008). Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 29: 1739-1752 [Abstract] [Full Text]  
• Popovic, Z. B., Thomas, J. D. (2008). In Search of a Holy Grail: Predicting Cardiac Resynchronization Therapy Outcomes by Echocardiography. Circ Cardiovasc Imaging 1: 3-5 [Full Text]  
• Miyazaki, C., Lin, G., Powell, B. D., Espinosa, R. E., Bruce, C. J., Miller, F. A. Jr, Karon, B. L., Rea, R. F., Hayes, D. L., Oh, J. K. (2008). Strain Dyssynchrony Index Correlates With Improvement in Left Ventricular Volume After Cardiac Resynchronization Therapy Better Than Tissue Velocity Dyssynchrony Indexes. Circ Cardiovasc Imaging 1: 14-22 [Abstract] [Full Text]  
• Prinzen, F. W., Auricchio, A. (2008). Is echocardiographic assessment of dyssynchrony useful to select candidates for cardiac resynchronization therapy?: Echocardiography Is Not Useful Before Cardiac Resynchronization Therapy if QRS Duration Is Available. Circ Cardiovasc Imaging 1: 70-78 [Full Text]  
• Fonarow, G. C., Yancy, C. W., Albert, N. M., Curtis, A. B., Stough, W. G., Gheorghiade, M., Heywood, J. T., McBride, M. L., Mehra, M. R., O'Connor, C. M., Reynolds, D., Walsh, M. N. (2008). Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings From IMPROVE HF. Circ Heart Fail 1: 98-106 [Abstract] [Full Text]  
• Gasparini, M., Auricchio, A., Metra, M., Regoli, F., Fantoni, C., Lamp, B., Curnis, A., Vogt, J., Klersy, C., for the Multicentre Longitudinal Observational Stu, (2008). Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 29: 1644-1652 [Abstract] [Full Text]  
• Kara, T., Novak, M., Nykodym, J., Bybee, K. A., Meluzin, J., Orban, M., Novakova, Z., Lipoldova, J., Hayes, D. L., Soucek, M., Vitovec, J., Somers, V. K. (2008). Short-term Effects of Cardiac Resynchronization Therapy on Sleep-Disordered Breathing in Patients With Systolic Heart Failure. Chest 134: 87-93 [Abstract] [Full Text]  
• Khadjooi, K, Foley, P W, Chalil, S, Anthony, J, Smith, R E A, Frenneaux, M P, Leyva, F (2008). Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. Heart 94: 879-883 [Abstract] [Full Text]  
• Kassai, I., Foldesi, C., Szekely, A., Szili-Torok, T. (2008). New method for cardiac resynchronization therapy: transapical endocardial lead implantation for left ventricular free wall pacing. Europace 10: 882-883 [Abstract] [Full Text]  
• Ferreira, A. M., Adragao, P., Cavaco, D. M., Candeias, R., Morgado, F. B., Santos, K. R., Santos, E., Silva, J. A. (2008). Benefit of cardiac resynchronization therapy in atrial fibrillation patients vs. patients in sinus rhythm: the role of atrioventricular junction ablation. Europace 10: 809-815 [Abstract] [Full Text]  
• Mandysova, E., Mraz, T., Taborsky, M., Niederle, P. (2008). Reproducibility of tissue Doppler parameters of asynchrony in patients with advanced LV dysfunction. Eur J Echocardiogr 9: 509-515 [Abstract] [Full Text]  
• Manisty, C. H., Willson, K., Davies, J. E. R., Whinnett, Z. I., Baruah, R., Mebrate, Y., Kanagaratnam, P., Peters, N. S., Hughes, A. D., Mayet, J., Francis, D. P. (2008). Induction of oscillatory ventilation pattern using dynamic modulation of heart rate through a pacemaker. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295: R219-R227 [Abstract] [Full Text]  
• Zanon, F., Aggio, S., Baracca, E., Pastore, G., Corbucci, G., Boaretto, G., Braggion, G., Piergentili, C., Rigatelli, G., Roncon, L. (2008). Ventricular-arterial coupling in patients with heart failure treated with cardiac resynchronization therapy: may we predict the long-term clinical response?. Eur J Echocardiogr 0: jen184v1-6 [Abstract] [Full Text]  
• Altin, T., Candemir, B., Ozkaramanli, D., Akyurek, O., Karaoguz, R., Guldal, M. (2008). Acute pulmonary oedema during cardiac resynchronization therapy device implantation: management with the activation of intra-aortic balloon pump. Europace 0: eun171v1-3 [Abstract] [Full Text]  
• Wang, N. C., Maggioni, A. P., Konstam, M. A., Zannad, F., Krasa, H. B., Burnett, J. C. Jr, Grinfeld, L., Swedberg, K., Udelson, J. E., Cook, T., Traver, B., Zimmer, C., Orlandi, C., Gheorghiade, M., for the Efficacy of Vasopressin Antagonism in Hear, (2008). Clinical Implications of QRS Duration in Patients Hospitalized With Worsening Heart Failure and Reduced Left Ventricular Ejection Fraction. JAMA 299: 2656-2666 [Abstract] [Full Text]  
• Sweeney, M. O., Prinzen, F. W. (2008). Ventricular Pump Function and Pacing: Physiological and Clinical Integration. Circ Arrhythmia Electrophysiol 1: 127-139 [Full Text]  
• Di Biase, L., Auricchio, A., Sorgente, A., Civello, K., Klersy, C., Faletra, F., Riedlbauchova, L., Patel, D., Arruda, M., Schweikert, R. A., Martin, D. O., Saliba, W. I., Moccetti, T., Wilkoff, B. L., Natale, A. (2008). The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. Eur Heart J 0: ehn221v1-9 [Abstract] [Full Text]  
• Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Estes, N.A. M. III, Freedman, R. A., Gettes, L. S., Gillinov, A. M., Gregoratos, G., Hammill, S. C., Hayes, D. L., Hlatky, M. A., Newby, L. K., Page, R. L., Schoenfeld, M. H., Silka, M. J., Stevenson, L. W., Sweeney, M. O. (2008). ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 51: e1-e62 [Full Text]  
• Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Mark Estes, N.A. III, Freedman, R. A., Gettes, L. S., Gillinov, A. M., Gregoratos, G., Hammill, S. C., Hayes, D. L., Hlatky, M. A., Newby, L. K., Page, R. L., Schoenfeld, M. H., Silka, M. J., Stevenson, L. W., Sweeney, M. O. (2008). ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 51: 2085-2105 [Full Text]  
• Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Estes, N.A. M. III, Freedman, R. A., Gettes, L. S., Gillinov, A. M., Gregoratos, G., Hammill, S. C., Hayes, D. L., Hlatky, M. A., Newby, L. K., Page, R. L., Schoenfeld, M. H., Silka, M. J., Stevenson, L. W., Sweeney, M. O. (2008). ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 117: 2820-2840 [Full Text]  
• Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Estes, N.A. M. III, Freedman, R. A., Gettes, L. S., Gillinov, A. M., Gregoratos, G., Hammill, S. C., Hayes, D. L., Hlatky, M. A., Newby, L. K., Page, R. L., Schoenfeld, M. H., Silka, M. J., Stevenson, L. W., Sweeney, M. O. (2008). ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 117: e350-e408 [Full Text]  
• Chung, E. S., Leon, A. R., Tavazzi, L., Sun, J.-P., Nihoyannopoulos, P., Merlino, J., Abraham, W. T., Ghio, S., Leclercq, C., Bax, J. J., Yu, C.-M., Gorcsan, J. III, St John Sutton, M., De Sutter, J., Murillo, J. (2008). Results of the Predictors of Response to CRT (PROSPECT) Trial. Circulation 117: 2608-2616 [Abstract] [Full Text]  
• Miyazaki, C., Powell, B. D., Bruce, C. J., Espinosa, R. E., Redfield, M. M., Miller, F. A., Hayes, D. L., Cha, Y.-M., Oh, J. K. (2008). Comparison of Echocardiographic Dyssynchrony Assessment by Tissue Velocity and Strain Imaging in Subjects With or Without Systolic Dysfunction and With or Without Left Bundle-Branch Block. Circulation 117: 2617-2625 [Abstract] [Full Text]  
• Butter, C., Rastogi, S., Minden, H.-H., Meyhofer, J., Burkhoff, D., Sabbah, H. N. (2008). Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure.. J Am Coll Cardiol 51: 1784-1789 [Abstract] [Full Text]  
• Buck, S., Rienstra, M., Maass, A. H., Nieuwland, W., Van Veldhuisen, D. J., Van Gelder, I. C. (2008). Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time. Europace 10: 558-565 [Abstract] [Full Text]  
• Haghjoo, M., Bagherzadeh, A., Farahani, M. M., Haghighi, Z. O., Sadr-Ameli, M. A. (2008). Significance of QRS morphology in determining the prevalence of mechanical dyssynchrony in heart failure patients eligible for cardiac resynchronization: particular focus on patients with right bundle branch block with and without coexistent left-sided conduction defects. Europace 10: 566-571 [Abstract] [Full Text]  
• Leclercq, C., Gadler, F., Kranig, W., Ellery, S., Gras, D., Lazarus, A., Clementy, J., Boulogne, E., Daubert, J.-C., for the TRIP-HF (Triple Resynchronization In Paced, (2008). A Randomized Comparison of Triple-Site Versus Dual-Site Ventricular Stimulation in Patients With Congestive Heart Failure. J Am Coll Cardiol 51: 1455-1462 [Abstract] [Full Text]  
• Anderson, L. J., Miyazaki, C., Sutherland, G. R., Oh, J. K. (2008). Patient Selection and Echocardiographic Assessment of Dyssynchrony in Cardiac Resynchronization Therapy. Circulation 117: 2009-2023 [Full Text]  
• Borggrefe, M. M., Lawo, T., Butter, C., Schmidinger, H., Lunati, M., Pieske, B., Misier, A. R., Curnis, A., Bocker, D., Remppis, A., Kautzner, J., Stuhlinger, M., Leclerq, C., Taborsky, M., Frigerio, M., Parides, M., Burkhoff, D., Hindricks, G. (2008). Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 29: 1019-1028 [Abstract] [Full Text]  
• Yoshida, K., Yokoyama, Y., Seo, Y., Sekiguchi, Y., Aonuma, K. (2008). Triangle ventricular pacing in a non-responder to conventional bi-ventricular pacing. Europace 10: 502-504 [Abstract] [Full Text]  
• Bourge, R. C., Abraham, W. T., Adamson, P. B., Aaron, M. F., Aranda, J. M. Jr, Magalski, A., Zile, M. R., Smith, A. L., Smart, F. W., O'Shaughnessy, M. A., Jessup, M. L., Sparks, B., Naftel, D. L., Stevenson, L. W., on behalf of the COMPASS-HF Study Group, (2008). Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study.. J Am Coll Cardiol 51: 1073-1079 [Abstract] [Full Text]  
• Inage, T., Yoshida, T., Hiraki, T., Ohe, M., Takeuchi, T., Nagamoto, Y., Fukuda, Y., Gondo, T., Imaizumi, T. (2008). Chronic cardiac resynchronization therapy reverses cardiac remodelling and improves invasive haemodynamics of patients with severe heart failure on optimal medical treatment. Europace 10: 379-383 [Abstract] [Full Text]  
• Albertsen, A. E., Nielsen, J. C., Poulsen, S. H., Mortensen, P. T., Pedersen, A. K., Hansen, P. S., Jensen, H. K., Egeblad, H. (2008). Biventricular pacing preserves left ventricular performance in patients with high-grade atrio-ventricular block: a randomized comparison with DDD(R) pacing in 50 consecutive patients. Europace 10: 314-320 [Abstract] [Full Text]  
• Bordachar, P., Labrousse, L., Thambo, J.-B., Reant, P., Lafitte, S., O'Neill, M. D., Jais, P., Haissaguerre, M., Clementy, J., Dos Santos, P. (2008). Haemodynamic impact of the left ventricular pacing site during graded ischaemia in an open-chest pig model. Europace 10: 242-248 [Abstract] [Full Text]  
• Okonko, D. O., Grzeslo, A., Witkowski, T., Mandal, A. K.J., Slater, R. M., Roughton, M., Foldes, G., Thum, T., Majda, J., Banasiak, W., Missouris, C. G., Poole-Wilson, P. A., Anker, S. D., Ponikowski, P. (2008). Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency: FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial. J Am Coll Cardiol 51: 103-112 [Abstract] [Full Text]  
• Vanderheyden, M., Mullens, W., Delrue, L., Goethals, M., de Bruyne, B., Wijns, W., Geelen, P., Verstreken, S., Wellens, F., Bartunek, J. (2008). Myocardial Gene Expression in Heart Failure Patients Treated With Cardiac Resynchronization Therapy: Responders Versus Nonresponders. J Am Coll Cardiol 51: 129-136 [Abstract] [Full Text]  
• Kass, D. A. (2008). An epidemic of dyssynchrony: but what does it mean?. J Am Coll Cardiol 51: 12-17 [Abstract] [Full Text]  
• Tops, L. F., Krishnan, S. C., Schuijf, J. D., Schalij, M. J., Bax, J. J. (2008). Noncoronary Applications of Cardiac Multidetector Row Computed Tomography. J Am Coll Cardiol Img 1: 94-106 [Abstract] [Full Text]  
• Pu, M., Abraham, W. T (2008). Resynchronisation therapy in heart failure: searching for predictors. Heart 94: 4-5 [Full Text]  
• Spotnitz, H. M. (2008). Surgical Implantation of Pacemakers and Automatic Defibrillators. Card Surg Adult 3: 1395-1428 [Full Text]  
• Lane, R E, Mayet, J, Peters, N S, Davies, D W, Chow, A W C (2008). Comparison of temporary bifocal right ventricular pacing and biventricular pacing for heart failure: evaluation by tissue Doppler imaging. Heart 94: 53-58 [Abstract] [Full Text]  
• Nof, E., Gurevitz, O., Carraso, S., Bar-Lev, D., Luria, D., Bachar, S., Eldar, M., Glikson, M. (2008). Comparison of results with different left ventricular pacing leads. Europace 10: 35-39 [Abstract] [Full Text]  
• Stollberger, C., Blazek, G., Bucher, E., Finsterer, J. (2008). Cardiac resynchronization therapy in left ventricular hypertrabeculation/non-compaction and myopathy. Europace 10: 59-62 [Abstract] [Full Text]  
• Stockburger, M., Fateh-Moghadam, S., Nitardy, A., Celebi, O., Krebs, A., Habedank, D., Dietz, R. (2008). Baseline Doppler parameters are useful predictors of chronic left ventricular reduction in size by cardiac resynchronization therapy. Europace 10: 69-74 [Abstract] [Full Text]  
• Duray, G. Z., Israel, C. W., Pajitnev, D., Hohnloser, S. H. (2008). Upgrading to biventricular pacing/defibrillation systems in right ventricular paced congestive heart failure patients: prospective assessment of procedural parameters and response rate. Europace 10: 48-52 [Abstract] [Full Text]  
• Mehra, M. R, Uber, P. A, Ventura, H. O (2007). Death messengers. BMJ 335: 1296-1297 [Full Text]  
• Beshai, J. F., Grimm, R. A., Nagueh, S. F., Baker, J. H. II, Beau, S. L., Greenberg, S. M., Pires, L. A., Tchou, P. J., the RethinQ Study Investigators, (2007). Cardiac-Resynchronization Therapy in Heart Failure with Narrow QRS Complexes. NEJM 357: 2461-2471 [Abstract] [Full Text]  
• Henneman, M. M., van der Wall, E. E., Ypenburg, C., Bleeker, G. B., van de Veire, N. R., Marsan, N. A., Chen, J., Garcia, E. V., Westenberg, J. J.M., Schalij, M. J., Bax, J. J. (2007). Nuclear Imaging in Cardiac Resynchronization Therapy. JNM 48: 2001-2010 [Abstract] [Full Text]  
• Sutton, R., Fisher, J. D., Linde, C., Benditt, D. G. (2007). History of electrical therapy for the heart. Eur Heart J Suppl 9: I3-I10 [Abstract] [Full Text]  
• Padeletti, L., Pieragnoli, P., Jentzen, V., Schuchert, A. (2007). The comorbidity of atrial fibrillation and heart failure: a challenge for electrical therapies. Eur Heart J Suppl 9: I81-I86 [Abstract] [Full Text]  
• Leclercq, C., Bleeker, G. B., Linde, C., Donal, E., Bax, J. J., Schalij, M. J., Daubert, C. (2007). Cardiac resynchronization therapy: clinical results and evolution of candidate selection. Eur Heart J Suppl 9: I94-I106 [Abstract] [Full Text]  
• Emkanjoo, Z., Esmaeilzadeh, M., Mohammad Hadi, N., Alizadeh, A., Tayyebi, M., Sadr-ameli, M.A. (2007). Frequency of inter- and intraventricular dyssynchrony in patients with heart failure according to QRS width. Europace 9: 1171-1176 [Abstract] [Full Text]  
• Ritter, P., Cazeau, S., Gras, D., Daubert, J.-C. (2007). Cardiac resynchronization therapy implantation: a blend of skill and technology. Eur Heart J Suppl 9: I107-I112 [Abstract] [Full Text]  
• Abraham, T. P., Dimaano, V. L., Liang, H.-Y. (2007). Role of Tissue Doppler and Strain Echocardiography in Current Clinical Practice. Circulation 116: 2597-2609 [Full Text]  
• Ypenburg, C., Lancellotti, P., Tops, L. F., Bleeker, G. B., Holman, E. R., Pierard, L. A., Schalij, M. J., Bax, J. J. (2007). Acute Effects of Initiation and Withdrawal of Cardiac Resynchronization Therapy on Papillary Muscle Dyssynchrony and Mitral Regurgitation. J Am Coll Cardiol 50: 2071-2077 [Abstract] [Full Text]  
• D'Andrea, A., Caso, P., Romano, S., Scarafile, R., Riegler, L., Salerno, G., Limongelli, G., Di Salvo, G., Calabro, P., Del Viscovo, L., Romano, G., Maiello, C., Santangelo, L., Severino, S., Cuomo, S., Cotrufo, M., Calabro, R. (2007). Different effects of cardiac resynchronization therapy on left atrial function in patients with either idiopathic or ischaemic dilated cardiomyopathy: a two-dimensional speckle strain study. Eur Heart J 28: 2738-2748 [Abstract] [Full Text]  
• Yoshida, K., Seo, Y., Yamasaki, H., Tanoue, K., Murakoshi, N., Ishizu, T., Sekiguchi, Y., Kawano, S., Otsuka, S., Watanabe, S., Yamaguchi, I., Aonuma, K. (2007). Effect of triangle ventricular pacing on haemodynamics and dyssynchrony in patients with advanced heart failure: a comparison study with conventional bi-ventricular pacing therapy. Eur Heart J 28: 2610-2619 [Abstract] [Full Text]  
• Bleeker, G. B, Yu, C.-M., Nihoyannopoulos, P., de Sutter, J., Van de Veire, N., Holman, E. R, Schalij, M. J, van der Wall, E. E, Bax, J. J (2007). Optimal use of echocardiography in cardiac resynchronisation therapy. Heart 93: 1339-1350 [Abstract] [Full Text]  
• Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9: 1006-1023 [Abstract] [Full Text]  
• Chalil, S., Foley, P. W.X., Muyhaldeen, S. A., Patel, K. C.R., Yousef, Z. R., Smith, R. E.A., Frenneaux, M. P., Leyva, F. (2007). Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace 9: 1031-1037 [Abstract] [Full Text]  
• Lane, R E, Chow, A W C, Mayet, J, Francis, D P, Peters, N S, Schilling, R J, Davies, D W (2007). The interaction of interventricular pacing intervals and left ventricular lead position during temporary biventricular pacing evaluated by tissue Doppler imaging. Heart 93: 1426-1432 [Abstract] [Full Text]  
• Albouaini, K., Egred, M., Alahmar, A., Wright, D. J. (2007). Cardiopulmonary exercise testing and its application. Postgrad. Med. J. 83: 675-682 [Abstract] [Full Text]  
• Johnson, L., Kim, H. K., Tanabe, M., Gorcsan, J., Schwartzman, D., Shroff, S. G., Pinsky, M. R. (2007). Differential effects of left ventricular pacing sites in an acute canine model of contraction dyssynchrony. Am. J. Physiol. Heart Circ. Physiol. 293: H3046-H3055 [Abstract] [Full Text]  
• Pijnappels, D. A., van Tuyn, J., de Vries, A. A.F., Grauss, R. W., van der Laarse, A., Ypey, D. L., Atsma, D. E., Schalij, M. J. (2007). Resynchronization of Separated Rat Cardiomyocyte Fields With Genetically Modified Human Ventricular Scar Fibroblasts. Circulation 116: 2018-2028 [Abstract] [Full Text]